Journal:

Article Title: Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy

doi: 10.1073/pnas.2435285100

Figure Lengend Snippet: The effects of KILLER/DR5, Bak inhibition, and caspase 8 or 9 inhibition on sensitization of Bax-/- cells to TRAIL after DNA damage. Bax-/- HCT116 cells were transfected with KILLER/DR5 siRNA (A) or Bak siRNA (B). LacZ siRNA oligos were used as a control. Twenty-four hours after transfection, cells were treated as described in the legend to Fig. 1. KILLER/DR5 and Bak expression were determined by Northern blots. Cells were harvested, stained with propidium iodide, and analyzed by flow cytometry. The sub-G1 content of 20,000 cells was examined for each sample. (C) Differential effects of caspase 8 (Z-IETD-FMK) and caspase 9 (Z-LEHD-FMK) inhibitors on TRAIL-induced apoptosis. Wild-type or Bax-/- HCT116 cells were pretreated with 10 μg/ml CPT-11 for 16 h, after which 20 μM caspase 8 or 9 inhibitor was added; after 2 h, TRAIL (10 ng/ml) plus 1 μg/ml anti-His-6 was added for 4 h before sub-G1 analysis. Extracts were collected and analyzed by Western blotting for the expression of caspase 9.

Article Snippet: Polyclonal antibody against caspase 9 was purchased from Imgenex (San Diego).

Techniques: Inhibition, Transfection, Expressing, Northern Blot, Staining, Flow Cytometry, Western Blot

Journal: Nucleic Acid Therapeutics

Article Title: Fit for the Eye: Aptamers in Ocular Disorders

doi: 10.1089/nat.2015.0573

Figure Lengend Snippet: Predicted secondary structure and free and bound NMR structures of t44-OMe. Photo-cross-linking site between the aptamer and Cys-134 on VEGF-165 is indicated.

Article Snippet: Fortunately, NeXstar (then NeXagen) had entered into a licensing agreement with Genentech (Genentech was one of the original investors) and this allowed us to obtain VEGF-165 as a generous gift from Dr. Napoleone Ferrara [ ].

Techniques: